Punit Dhillon

Punit Dhillon, Chairman and CEO of Skye Bioscience, shares insights on innovative obesity therapies targeting CB1 inhibition. He discusses the challenges faced by recent GLP-1 inhibitors and proposes a groundbreaking antibody-based approach to minimize side effects. Dhillon emphasizes the importance of combining effective treatments with lifestyle changes to tackle obesity's complex nature. With a commitment to rigorous clinical trials and a focus on metabolic health, he highlights Skye's potential to disrupt the weight-loss therapeutic market significantly.